Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugsnews2026-06-08T13:52:14+00:00June 8th, 2026|Endpoints News|
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotnews2026-06-08T13:17:32+00:00June 8th, 2026|Endpoints News|
Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealnews2026-06-08T11:03:56+00:00June 8th, 2026|Endpoints News|
Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealnews2026-06-08T11:01:03+00:00June 8th, 2026|Endpoints News|
Nurix to work with Roche on BTK degrader in pact worth up to $2.3Bnews2026-06-08T10:57:19+00:00June 8th, 2026|Endpoints News|
#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsnews2026-06-07T18:30:38+00:00June 7th, 2026|Endpoints News|
#ADA26: Pfizer monthly shot shows effect on obesity, diabetesnews2026-06-06T13:00:02+00:00June 6th, 2026|Endpoints News|
#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearnews2026-06-06T10:44:27+00:00June 6th, 2026|Endpoints News|
Lawmakers propose China restrictions; #ASCO26 recap; and morenews2026-06-06T10:00:31+00:00June 6th, 2026|Endpoints News|
#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesnews2026-06-05T22:30:23+00:00June 5th, 2026|Endpoints News|
